Currently out of the existing stock ratings of Matthew Mishan, 137 are a BUY (91.95%), 12 are a HOLD (8.05%).

Matthew Mishan

Work Performance Price Targets & Ratings Chart

Analyst Matthew Mishan, currently employed at KEYBANK, carries an average stock price target met ratio of 66.52% that have a potential upside of 22.39% achieved within 253 days.

Matthew Mishan’s has documented 301 price targets and ratings displayed on 22 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on AGTI, Agiliti at 09-Aug-2023.

Wall Street Analyst Matthew Mishan

Analyst best performing recommendations are on AGTI (AGILITI).
The best stock recommendation documented was for AGTI (AGILITI) at 5/18/2021. The price target of $21 was fulfilled within 8 days with a profit of $5.81 (38.25%) receiving and performance score of 47.81.

Average potential price target upside

of $78.01 (40.75%) on RMD (RESMED).
of $49.43 (24.21%) on BDX (BECTON DICKINSON AND COMPANY).
of $44.96 (20.6%) on TFX (TELEFLEX).

AGTI Agiliti AVNS Avanos Medical BAX Baxter International BDX Becton Dickinson and Company HRC Hill-Rom Holdings ICUI ICU Medical ITGR Integer Holdings Corp RMD ResMed STE STERIS plc TFX Teleflex ANGO AngioDynamics COO The Cooper Companies Common Stock CTLT Catalent INGN Inogen SHC Sotera Health Co AVTR Avantor INSP Inspire Medical Systems PKI PerkinElmer PRCT Procept Biorobotics Corp AXNX Axonics Modulation Technologies CNMD CONMED IVC Invacare

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

John Ransom (RAYMOND JAMES)